Hepatitis and lupus-like syndrome during infliximab therapy for psoriasis

Case Reports in Dermatology

Volumn 5, Issue 2, 2013, Pages 219-224

  Riad, Hassan ^a   Abu Shaikha, Samya ^a   Al Ansari, Hamda ^a   Al Naama, Khalifa ^a   Al Sada, Hussein ^a   Al Mansoori, Mariam ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Hepatitis; Infliximab therapy; Lupus like syndrome; Psoriasis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BILIRUBIN; C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; HISTONE ANTIBODY; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; SALAZOSULFAPYRIDINE; SM ANTIBODY; USTEKINUMAB;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE HEPATITIS; CASE REPORT; CORTICOSTEROID THERAPY; DEPRESSION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EFFUSION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; INJECTION SITE HYPERSENSITIVITY; LETHARGY; LIVER FUNCTION TEST; LUPUS LIKE SYNDROME; MYALGIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; SIDE EFFECT; SWELLING; TOPICAL TREATMENT; TREATMENT RESPONSE; YOUNG ADULT;

EID: 84884254096     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000354593     Document Type: Article

References (10)

1. Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFa agents. J Dtsch Dermatol Ges. 2012; 10: 889-897
2. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-Tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009; 84: 979-984
3. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network: Liver injury from tumor necrosis factor-A antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013; 11: 558-564.e3
4. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007; 156: 329-336
5. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group: Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013; 25: 56-64
6. Poulin Y, Thérien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg. 2010; 14: 100-104
7. Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol DOI: 10.1111/ajd.12054
8. Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, Costa Santos C. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008; 14: 723-725
9. Koshy JM, John M. Autoimmune hepatitis - SLE overlap syndrome. J Assoc Physicians India. 2012; 60: 59-60
10. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-To-severe plaque psoriasis. J Am Acad Dermatol. 2007; 56: 31.e1-31.e15